In-vitro Susceptibility Testing Methods for Ceftazidime-avibactam against Carbapenem-resistant Enterobacterales: Comparison with Reference Broth Microdilution Method

被引:0
|
作者
Sharma, Bhawna [1 ]
Sreenivasan, Priya [1 ]
Angrup, Archana [1 ]
Kaur, Satinder [1 ]
Rana, Sudesh [1 ]
Kundu, Jyoti [1 ]
Biswal, Manisha [1 ]
Ray, Pallab [1 ]
机构
[1] PGIMER, Dept Med Microbiol, Chandigarh 160012, India
关键词
Ceftazidime-avibactam; carbapenem; resistant; Enterobacterales; disk diffusion; broth microdilution; BETA-LACTAMASES; SURVEILLANCE; GENES;
D O I
10.2174/1574886318666221209160323
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: beta-lactam antibiotics, mainly cephalosporins, and carbapenems, have been the mainstay of treatment for infections caused by Enterobacterales. However, their role in treating clinical infections has become limited because of the increase in resistance. There is a need to have cost-effective and rapid methods for antimicrobial susceptibility testing methods for newer antibiotics like ceftazidime-avibactam against carbapenem-resistant Enterobacterales (CRE), which can be applied in routine clinical microbiology laboratories. With this aim, the present study was conducted to compare the disk diffusion and gradient diffusion, i.e., the E-test method with the reference broth microdilution (BMD) method for in-vitro testing of ceftazidime-avibactam against CRE. Materials and Methods: A total of 111 CRE isolates from various clinical samples were included. Conventional PCR (Polymerase Chain Reaction) was done for the detection of genes encoding carbapenemases and to see their expression, modified carbapenem inactivation method (mCIM) along with EDTA (Ethylenediaminetetraacetic acid) carbapenem inactivation method (eCIM) was done. Results: 42.3% (47/111) isolates were resistant to ceftazidime-avibactam by the standard broth microdilution method; however, 45.9% (51/111) were resistant by both disk diffusion and E-test. In 5.4% of isolates (similar in both methods), microbroth dilution method results did not match with E-strip and disk diffusion. Very major errors (VME) by both disk diffusion and E-test were found in 2.1% (1/47), and major errors (ME) were found in 7.8% (5/64) isolates (similar isolates in both methods). The overall categorical agreement (CA) rate was 94.6% for both E-test and disk diffusion, and the essential agreement (EA) rate was 90.1% (100/111) for E-test. 98% (109/111) of CRE harbored carbapenemase genes either singly (30.3%) or in combination with others (69.7%). Conclusion: In conclusion, for CRE, E-test and the disk diffusion method for ceftazidime-avibactam depicted an acceptable performance as an alternative to the reference broth microdilution method.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 50 条
  • [41] Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Enterobacterales Clinical Isolates
    Han, Renru
    Yang, Xuelin
    Yang, Yang
    Guo, Yan
    Yin, Dandan
    Ding, Li
    Wu, Shi
    Zhu, Demei
    Hu, Fupin
    [J]. MICROBIOLOGY SPECTRUM, 2022, 10 (01):
  • [42] Comparison of in Vitro Antimicrobial Efficacy of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Combination Against Carbapenem-Resistant Enterobacteriaceae Species Isolated from Various Clinical Specimens
    Guzel, Mustafa
    Ocal, Duygu
    Onder, Ilke Toker
    Akdogan, Dogan
    Erdem, Gul Bahar
    Akpinar, Orhan
    [J]. KONURALP TIP DERGISI, 2022, 14 (01): : 75 - 80
  • [43] Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope (vol 22, 21, 2023)
    Taha, Rawan
    Kader, Ola
    Shawky, Sherine
    Rezk, Shahinda
    [J]. ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2023, 22 (01)
  • [44] In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019
    Bakthavatchalam, Yamuna Devi
    Routray, Abhisek
    Mane, Akshata
    Kamat, Shweta
    Gupta, Anu
    Bari, Anurag Kumar
    Rohit, Anusha
    Poojary, Aruna
    Mukherjee, Dip Narayan
    Sethuraman, Nandini
    Munshi, Nita
    Shah, Sweta
    Balaji, Veeraraghavan
    Gupta, Yogesh
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 103 (01)
  • [45] Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales
    Vena, Antonio
    Giacobbe, Daniele Roberto
    Castaldo, Nadia
    Cattelan, Annamaria
    Mussini, Cristina
    Luzzati, Roberto
    De Rosa, Francesco Giuseppe
    Del Puente, Filippo
    Mastroianni, Claudio Maria
    Cascio, Antonio
    Carbonara, Sergio
    Capone, Alessandro
    Boni, Silvia
    Sepulcri, Chiara
    Meschiari, Marianna
    Raumer, Francesca
    Oliva, Alessandra
    Corcione, Silvia
    Bassetti, Matteo
    [J]. ANTIBIOTICS-BASEL, 2020, 9 (02):
  • [46] Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
    Guanhao Zheng
    Jianxin Zhang
    Bei Wang
    Jiaqi Cai
    Lili Wang
    Kaixuan Hou
    Yan Zhang
    Liang Zhang
    Zhitao Yang
    Juan He
    Xiaolan Bian
    [J]. Infectious Diseases and Therapy, 2021, 10 : 1699 - 1713
  • [47] Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study
    Zheng, Guanhao
    Zhang, Jianxin
    Wang, Bei
    Cai, Jiaqi
    Wang, Lili
    Hou, Kaixuan
    Zhang, Yan
    Zhang, Liang
    Yang, Zhitao
    He, Juan
    Bian, Xiaolan
    [J]. INFECTIOUS DISEASES AND THERAPY, 2021, 10 (03) : 1699 - 1713
  • [48] Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae
    Tuzemen, Nazmiye Ulku
    Onal, Ugur
    Merdan, Osman
    Akca, Bekir
    Ener, Beyza
    Ozakin, Cuneyt
    Akalin, Halis
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01):
  • [49] Polymyxin B resistance rates in carbapenem-resistant Pseudomonas aeruginosa isolates and a comparison between Etest(R) and broth microdilution methods of antimicrobial susceptibility testing
    Chen, Xu
    Xu, Jie
    Zhu, Qiongfang
    Ren, Yalu
    Zhao, Lina
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (02) : 762 - 769
  • [50] In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
    Li, Dan
    Yu, Hua
    Huang, Xiangning
    Long, Shanshan
    Zhang, Jie
    [J]. MICROBIOLOGY SPECTRUM, 2023, 11 (06):